Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Immunological Methods|April 2, 2003
T cell stimulation and expansion using anti-CD3/CD28 beadsAnnette Trickett, Yiu Lam Kwan
International Journal of Hematology|July 4, 2002
Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemiaArumugam Manoharan, Annette Trickett, Yiu Lam Kwan, et al.
Journal of Immunological Methods|May 2, 2002
Ex vivo expansion of functional T lymphocytes from HIV-infected individualsAnnette E Trickett, Yiu Lam Kwan, Barbara Cameron, et al.
Internal Medicine Journal|March 26, 2019
Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology settingKelvin Truong, Yiu Lam Kwan, Lucia Nigro, et al.
Blood Cancer Journal|March 15, 2020
A liquid biopsy to detect multidrug resistance and disease burden in multiple myelomaSabna Rajeev Krishnan, Gabriele De Rubis, Hayley Suen, et al.
World Journal of Gastroenterology|May 29, 2015
Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's diseaseNeil R Moran, Bradley Webster, Kenneth M Lee, et al.
British Journal of Clinical Pharmacology|February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationChrista E Nath, Judith Trotman, Campbell Tiley, et al.
Internal Medicine Journal|October 19, 2016
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practiceJudith Trotman, Jimmy Trinh, Yiu Lam Kwan, et al.
British Journal of Clinical Pharmacology|June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapyChrista E Nath, Peter J Shaw, Judith Trotman, et al.
Blood|March 5, 2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyIan W Flinn, Richard van der Jagt, Brad S Kahl, et al.
Pageof 2